Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment

Gene Felber, PhD, Chi-Chang Chen, Jenny Willson, Chris Bell, Edgar Simard, Sasikiran Nunna, Chandrabhan Dharmani, Heide Stirnadel-Farrant, Feng Wang, Amanda Bruno

Blood (2019) 134 (Supplement_1): 4725.

https://doi.org/10.1182/blood-2019-130791

Published: 2019

Journal Articles

Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Jenny Willson, Amanda Bruno, Joanna Opalinska, Jeannene Nelson, Orsolya Lunacsek, Dana Stafkey-Mailey, Joanne Willey

Blood (2018) 132 (Supplement 1): 3290.

https://doi.org/10.1182/blood-2018-99-112954

Published: 2018

Journal Articles

Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Amin N Alpesh, MBA, MD, Allison Keshishian, MPH, Lin Xie, MA, MS, Onur Baser, MS, PhD, Kwanza Price, MPH, Lien Vo, MPH, PharmD, Prianka Singh, PharmD, Amanda Bruno, MPH, PhD, Jack Mardekian, PhD, Wilson Tan, MRCS, MD, Shalabh Singhal, MD, Chad Patel, PharmD, Kevin Odell, PharmD, Jeffrey Trocio, MPH

Blood (2015) 126 (23): 745.

https://doi.org/10.1182/blood.V126.23.745.745

Published: 2015

Journal Articles

Estimate of Real-World Medical Costs Avoidance When New Oral Anticoagulants Are Used Vs. Standard Therapy for the Treatment of Patients with Venous Thromboembolism in the U.S

Alpesh N Amin, MDMBA, Amanda Bruno, PhD MPH, Jeffrey Trocio, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD

Blood (2014) 124 (21): 687.

https://doi.org/10.1182/blood.V124.21.687.687

Published: 2014

Journal Articles

Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S

Alpesh N Amin, MDMBA, Amanda Bruno, PhD MPH, Jeffrey Trocio, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD

Blood (2014) 124 (21): 2181.

https://doi.org/10.1182/blood.V124.21.2181.2181

Published: 2014

NARROW

US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment

Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Estimate of Real-World Medical Costs Avoidance When New Oral Anticoagulants Are Used Vs. Standard Therapy for the Treatment of Patients with Venous Thromboembolism in the U.S

Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S

Email alerts

ASH Publications

American Society of Hematology

US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment

Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Estimate of Real-World Medical Costs Avoidance When New Oral Anticoagulants Are Used Vs. Standard Therapy for the Treatment of Patients with Venous Thromboembolism in the U.S

Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only